Health Care & Life Sciences » Biotechnology | Chabiotech Co. Ltd.

Chabiotech Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
310,232
212,786
265,808
323,601
293,817
Total Accounts Receivable
91,245
123,963
83,651
112,695
141,330
Inventories
15,476
7,615
9,090
11,456
14,659
Other Current Assets
11,482
13,599
11,551
15,260
25,255
Total Current Assets
428,436
357,963
370,100
463,012
475,060
Net Property, Plant & Equipment
138,464
130,487
143,513
159,161
169,514
Total Investments and Advances
36,421
53,466
33,059
42,330
66,071
Long-Term Note Receivable
-
-
5,860
5,867
4,500
Intangible Assets
62,092
58,005
50,347
53,455
40,357
Other Assets
14,903
16,136
33,974
39,032
41,995
Total Assets
685,466
620,885
644,831
768,929
803,339
ST Debt & Current Portion LT Debt
19,216
8,854
35,234
177,374
50,516
Accounts Payable
30,323
14,670
19,663
27,729
17,474
Income Tax Payable
3,381
8,870
4,220
382
160
Other Current Liabilities
49,900
67,350
56,402
60,644
154,046
Total Current Liabilities
102,819
99,743
115,519
266,129
222,196
Long-Term Debt
5,188
14,638
5,792
32,439
76,575
Provision for Risks & Charges
22,620
24,917
26,460
26,531
22,261
Deferred Taxes
2,834
4,494
4,373
3,416
3,623
Other Liabilities
40,178
43,798
46,893
62,313
53,150
Total Liabilities
173,121
183,430
198,268
390,068
376,403
Common Equity (Total)
383,757
297,225
290,103
286,321
242,755
Total Shareholders' Equity
383,757
297,225
290,103
286,321
242,755
Total Equity
512,345
437,454
446,563
378,861
426,937
Liabilities & Shareholders' Equity
685,466
620,885
644,831
768,929
803,339
Accumulated Minority Interest
128,588
140,229
156,460
92,540
184,182

About Chabiotech Co.

View Profile
Address
3rd Floor, Pie'n Polus Building
Seoul SL 06062
Korea, Republic Of
Employees -
Website http://www.chabio.co.kr
Updated 09/14/2018
Cha Biotech Co., Ltd. engages in the research of cell therapy and storage of cord blood. It operates through the following business: Cell Therapy Development, Bio, Chaum, and Bio Insurance. The Cell Therapy Development business develops and commercializes cell therapy.